Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2018 / Cilt: 27 - Sayı: 3

Complement Factor H and Complement Factor H-Related Protein 5 Mutations Associated with Atypical Hemolytic Uremic Syndrome in a Systemic Lupus Erythematosus Patient: Efficacy of Eculizumab

Atipik Hemolitik Üremik Sendrom ile Başvuran Sistemik Lupus Eritematozus Olgusunda Kompleman Faktör H ve Kompleman Faktör H-İlişkili Protein 5 Mutasyonları: Ekulizumab Etkinliği

Pages
308–312
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient was refractory to immunosuppressives andplasmapheresis but responded well to eculizumab

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atypical hemolytic uremic syndrome (aHUS) is a disorder characterized by a propensity to thromboticmicroangiopathy (TMA) due to defective regulation of the alternative complement pathway.
📊
Key Findings & Data:We describe a SLE patient with severe AKI dueto aHUS related CFH and CFHR5 mutations.
💡
Conclusion & Impact:The patient was refractory to immunosuppressives andplasmapheresis but responded well to eculizumab
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a disorder characterized by a propensity to thromboticmicroangiopathy (TMA) due to defective regulation of the alternative complement pathway. Mutationsin genes encoding complement factor H (CFH) and complement factor H-related proteins (CFHR) canbe related with aHUS and identified in patients with rheumatologic diseases.Atypical HUS typically presents as acute kidney injury (AKI) associated with microangiopathichemolytic anemia (MAHA) and thrombocytopenia. We describe a SLE patient with severe AKI dueto aHUS related CFH and CFHR5 mutations. The patient was refractory to immunosuppressives andplasmapheresis but responded well to eculizumab

Özet

Atipik hemolitik üremik sendrom (aHUS) alternatif kompleman yolağının kontrolündeki kusura bağlı trombotik mikroanjiyopati (TMA) yatkınlığı ile karakterize bir bozukluktur. Kompleman bileşenlerinden kompleman faktör H (CFH) ve CFH-ilişkili protein (CFHR) mutasyonları aHUS ile ilişkilidir ve bazı romatolojik hastalıklara da eşlik edebilir. AHUS tipik olarak akut böbrek hasarı (ABH) ile birlikte mikroanjiyopaik hemolitik anemi ve trombositopeni ile ortaya çıkmaktadır. Ciddi ABH ile başvuran Sistemik Lupus Eritematozus (SLE) olgumuzda aHUS ilişkili CFH ve CFHR5 mutasyonları saptadık. İmmünsüpresif tedavi ve plazmafereze dirençli olan olguda ekulizumab tedavisine yanıt alındı.

🔖

Cite This Article

ERSAN, S., YILMAZ, B. A., ERKUL, B., YILMAZ, Z., GÜLLE, S. (2022). Complement Factor H and Complement Factor H-Related Protein 5 Mutations Associated with Atypical Hemolytic Uremic Syndrome in a Systemic Lupus Erythematosus Patient: Efficacy of Eculizumab. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 27 - Sayı: 3, 308–312. https://ajindex.com/articles/636082

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-657
  2. Raufi AG, Scott S, Drwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran MH: Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab. Hematol Rep 2016;8:6625- 6628 Tsai HM: A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev 2014;28:187-197
  3. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT: Complement factor H related proteins (CFHRs). Mol Immunol 2013;56:170-180
  4. Rodriguez de Cordoba S, Tortajada A, Harris CL, Morgan BP: Complement dysregulation and disease: From genes and proteins to diagnostics and drugs. Immunobiology 2012;217:1034-1046
  5. Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, Van Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L: Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 2010;25:2195-2202
  6. Dragon-Durey MA, Fremeaux-Bacchi V: Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immun 2005;27:359-374
  7. Nester CM, Barbour T, Rodriguez de Cordoba S, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship THJ, Kavanagh, D, Noris M, Pickering M, Sanchez-Corral,P, Skerka C, Zipfel P, Smith RJH: Atypical aHUS: State of the art. Mol Immunol 2015;67:31-42
  8. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-1859
  9. Jönsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG, Bengtsson A, Zickert A, Eloranta ML, Truedsson L, Rönnblom L, Nordmark G, Sturfelt G, Blom AM: Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 2011;13:R206 Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcón-Riquelme ME: Association of genetic variants in complement factor H and factor H-related genes with systemic